Effects of Ursodeoxycholic Acid on Inflammatory Markers IL-6 and IL-17 in Patients with Metabolic Syndrome
Schlagworte:
Metabolic Syndrome, Ursodeoxycholic Acid, Inflammatory Markers, Interleukin-6, ObesityAbstract
Metabolic syndrome encompasses a cluster of factors that significantly heighten the risk of cardiovascular disease and type 2 diabetes mellitus. This study explores the impact of Ursodeoxycholic acid on inflammatory markers, specifically interleukins IL-6 and IL-17, in patients with MS. Forty patients with MS, aged 25–55, were evaluated, with a control group of 30 healthy individuals. Serum levels of IL-6 and IL-17 were measured before and after 30 days of UDCA therapy (500 mg daily), alongside a hypocaloric diet. Patients were stratified by blood pressure (BP) and body mass index (BMI) to examine associations with cytokine levels. Pre-treatment, IL-6 and IL-17 levels in MS patients were significantly higher than in controls. Post-treatment results indicated a notable reduction in IL-6, particularly in the obese subgroup (BMI >30 kg/m²), though IL-17 levels remained largely unchanged. These findings suggest that UDCA may help modulate IL-6-driven inflammation in MS, especially among obese patients, while IL-17 requires additional therapeutic targeting. Limitations include the study’s short duration, small sample size, and absence of placebo control. Future research should investigate long-term outcomes and the effects of UDCA on broader inflammatory pathways in MS to enhance therapeutic approaches.
Literaturhinweise
Schwartz, V. (2009). Regulation of metabolic processes of interleukin-6. Cytokines and Inflammation Journal, (3), 3–10.
Pirogova, I. Y., Yakovleva, S. V., Neuymina, T. V., et al. (2019). Pleiotropic effects of ursodeoxycholic acid in non-alcoholic fatty liver disease and metabolic syndrome. Consilium Medicum, 21(8), 65–70. https://doi.org/10.26442/20751753.2019.8.190365
Tanchenko, O. A., Naryshkin, S. V., & Sivyakova, O. N. (2012). Ursodeoxycholic acid in the complex treatment of patients with metabolic syndrome. Russian Journal of Gastroenterology, Hepatology, Coloproctology, 22(1), 82–86. ISSN: 1382-4376; eISSN: 2658-6673
Wisse, B. E. (2014). The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity. Journal of the American Society of Nephrology, 15, 2792–2800.
Khalimova, Kh. M., Memetov, F. Yu., & Raimova, M. M. (2015). Dynamics of cellular and humoral immunity indicators in patients with ischemic stroke undergoing “TAF” Lactoflor treatment. Bulletin of the Kazakh National Medical University, (4), 232–233.
National Cholesterol Education Program (NCEP) Expert Panel. (2012). Third report on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation, 106, 3143–3421. The 2001 NCEP report sparked increased interest in metabolic syndrome, leading to new research and debate on its clinical utility.
Grundy, S. M., et al. (2014). Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 109, 433–438.
Grundy, S. M., et al. (2014). Clinical management of metabolic syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation, 109, 551–556.
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2015). The metabolic syndrome: Epidemiology, mechanisms, and therapy. The Lancet, 365, 1415–1428.
Isomaa, B., et al. (2011). Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24, 683–689.
Lakka, H. M., et al. (2012). The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 288, 2709–2716.
Sattar, N., et al. (2013). Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation, 108, 414–419.
Girman, C. J., et al. (2014). The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Cardiology, 93, 136–141.
Malik, S., et al. (2014). Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation, 110, 1245–1250.
Olijhoek, J. K., et al. (2014). The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease, or abdominal aortic aneurysm. European Heart Journal, 25, 342–348.
Alexander, C. M., et al. (2013). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes, 52, 1210–1214.
Ninomiya, J. K., et al. (2014). Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation, 109, 42–46.
McNeill, A. M., et al. (2015). The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities study. Diabetes Care, 28, 385–390.
Solymoss, B. C., et al. (2013). Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease. Coronary Artery Disease, 14, 207–212.
Grundy, S. M., et al. (2015). Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 112, 2735–2752.
